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Summary A review of misonidazole pharmacokinetics in 83 consecutive patients treated for tumours other
than glioma has shown that among patients not receiving enzyme-inducing agents the plasma elimination half
life is lower in patients taking steroids. Such a difference is not seen if patients already taking enzyme
inducers are given steroids.
Five further patients with carcinoma of the lung, treated with radiation over a period of 3 weeks, have been
studied in greater detail. Misonidazole, in oral dose of 1 g m-2, was given in conjunction with the first and last
radiotherapy fractions, and dexamethasone, in a divided daily dose of 8 mg, was given throughout the
radiation treatment, commencing after the first treatment. Misonidazole pharmacokinetics were studied at
each administration. Following the dexamethasone treatment period there was a 25% reduction in
misonidazole plasma elimination half life, a 24% reduction in plasma AUCO-o,, and a 38% increase in 24h
urinary excretion (all changes being statistically significant-P<0.005). No changes were observed in the
plasma AUCO-24 and urinary excretion of the major metabolite desmethylmisonidazole. Glomerular filtration
rates in one patient, before and after treatment with dexamethasone, remained unchanged. These results
suggest that the effect of dexamethasone on misonidazole kinetics is not related to an enhancement of
demethylation.
The limiting factor in the clinical use of
misonidazole (MISO) as a radiosensitizer is its
neurotoxicity and, because of this, a maximum oral
dose of 12gm 2 is usually advocated (Dische et al.,
1977; Urtasun et al., 1978; Wasserman et al., 1979;
Bleehen, 1980). In a fractionated course of
radiotherapy, it is likely that the dose of MISO
given with each treatment is inadequate to produce
measurable radiosensitization. This has led
investigators to study the role of pretreatment with
enzyme inducers (phenytoin, phenobarbitone,
antipyrene), such that the resulting reduction in
half life and area under the curve (AUC) may allow
an increase in dose, without any increase in toxicity
(Bleehen, 1980; Workman et al., 1980; Wasserman
et al., 1980; Moore et al., 1981). Such a theoretical
basis does not prove to be as satisfactory as
expected in the clinical setting, in that, despite the
above changes in MISO plasma pharmacokinetics,
the incidence of neurotoxicity remains unchanged,
and the dose of MISO cannot safely be increased
above 12gm 2 (Jones et al., 1983).
It has been noted that patients with glioma,
treated with radiotherapy and MISO, may not
show the expected incidence of central and/or
peripheral neurotoxicity (Bleehen, 1980). That these
patients are concurrently taking enzyme-inducing
anticonvulsants may be a plausible explanation for
this observation, but in the light of our other recent
studies mentioned above (Jones et al., 1983) this
hypothesis does not seem to be acceptable.
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Frequently, patients with gliomas are given
glucocorticoids for the control of cerebral oedema
either due to the tumour itself or due to surgery or
radiotherapy. Dexamethasone is the drug most
usually used. Initial studies in laboratory animals
showed that dexamethasone does not seem to affect
the plasma pharmacokinetics of MISO (Workman,
1980a). Further, a review of MISO plasma
pharmacokinetics in a heterogeneous group of 83
patients indicated that, in man, both enzyme
inducers and dexamethasone influence the body's
handling of MISO. For this reason, within patient
plasma pharmacokinetic studies were executed to
elucidate further the 'protective' property of
dexamethazone in patients taking MISO.
Materials and methods
In the heterogeneous group of 83 consecutive
patients receiving MISO in various doses whilst
undergoing radiation therapy for a spectrum of
tumours other than glioma, 43 were not taking
steroids or enzyme inducers (phenytoin and/or
phenobarbitone); 10 were taking steroids, but not
any enzyme inducers; 25 were taking enzyme
inducers, but no steroids; 5 were taking both
steroids and enzyme inducers. The present study
investigated 5 patients (4 males, 1 female) of mean
age 50 years (range 35-68), who were previously
untreated and who were not taking any other
medication. In view of the recognised complications
of steroid therapy, we felt that it was unethical to
give steroids to patients who would not otherwise
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receive them as part of their radiotherapy. It was
for this reason that the patients entered into the
study were those with impending main bronchial
obstruction due to carcinoma of the lung. They
received 3150cGy in 9 fractions,3 times weekly over
3 weeks, to their lung tumours. MISO, in doses of
gm-2, was given orally 4h before the first and
last radiation fractions. After the first fraction, oral
dexamethasone, in a dose of 2 mg four times a day,
was commenced and was continued for the
duration of the treatment.
The patients were admitted to hospital for their
first and last treatments so that misonidazole
pharmacokinetic studies could be performed. Blood
samples were taken at 1, 4, 8, 12 and 24h following
the administration of misonidazole, and 24h urine
collections were made during the blood sampling
periods. Prior to starting treatment, plasma urea
and creatinine, serum proteins, albumin, alanine
aminotransferase and alkaline phosphatase were
measured as indices of renal and hepatic function.
Plasma and urinary MISO and
desmethylmisonidazole were estimated by high
performance liquid chromotography (Workman et
al., 1978) and calculation of pharmacokinetic
parameters was carried out as described previously
(Workman, 1980b). One patient agreed to undergo
51Cr-EDTA clearance studies as an index of
glomerular filtration rate on the two occasions of
MISO adminstration.
The patients' informed consent for the
investigation was obtained and the study was
approved by the hospital ethical committee.
Results
There were no acute adverse reactions due to
dexamethasone or MISO. All patients completed
their radiation regimen without deviation from the
protocol. Pretreatment renal and hepatic function
Table I Plasma elimination half lives of MISO in
patients taking steroids and/or enzyme inducers or neither
(n=83)
Plasma halflife (h) ±sd
p
(unpaired
Steroids No steroids "t" test)
No enzyme inducers 9.8+3.29 12.3+2.8 0.04
(n=10) (n=43)
Enzyme inducers 7.7+ 1.5 8.3+ 1.7 0.4
(n=5) (n=25)
was normal in all patients. Table I shows the results
obtained from the heterogeneous group of 83
patients. The plasma elimination half life of MISO
of patients taking steroids was significantly lower
than in patients not taking steroids (9.8h and 12.3h
respectiviely [P=0.04, unpaired "t" test]); but such
a difference was not seen if patients were also
taking enzyme inducing agents (7.7h and 8.3h).
Table II describes the mean results from the 5
patients in the present study. The cumulative
plasma concentration time curves for MISO and
desmethylmisonidazole are shown in Figure 1
together with a representative set of curves from an
individual patient. Following dexamethasone
treatment, there was a 25% fall in MISO half life
(from 11.2+0.8h [±sd] to 8.4+0.7h; P<0.005).
The increased plasma clearance of MISO after
dexamethasone is also indicated by the 24%
reduction in AUCO8 (from 711+94pg.ml-1.h to
544+108pg.ml-1.h; P<0.005 [paired "t" test])
and the 38% increase in 24h urinary MISO (from
175+47lig per 24h to 284+77pg per 24h;
P <0.005).
No change was observed in the urinary excretion
of desmethyl-MISO or in its AUCG024' The peak
Table II Summary of changes in pharmacokinetic indices of MISO (1 gm-2 single oral
dose) following treatment with dexamethasone (8mg daily for 3 weeks) Mean ±sd; n=5)
p
MISO Pretreatment Post treatment (paired "t" test)
t- (h) 11.2+0.8 8.4+0.7 <0.005
AUC024 (pg.ml .h) 536+64 463+86 <0.05
AUC,,, (pg.ml .h) 711+94 544+ 108 <0.005
Peak concentration (pgml1) 37.7+4.6 43.6+9.9 NS
Urinary excretion (ug/24h) 175+47 284+77 <0.005
Desmethyl Misonidazole
Peak concentration (ugml 1) 4.28 +0.89 4.06+0.51 NS
Urinary excretion (ug/24h) 272+55 269+97 NS
AUC024 (pg.ml-1. h) 82+20 74+7 NSDEXAMETHASONE AND MISONIDAZOLE PHARMACOKINETICS 555
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Figure 1 Plasma elimination pharmacokinetics of MISO (1g.m-2 single oral dose) (a) mean results of
5 patients; (b) representative results of one patient before and after 3 weeks' treatment with dexamethasone
(8mg daily). Pre dexamethasone: (* *) MISO; (0 0) Desmethylmisonidazole. Post dexamethasone:
(A---,) MISO; (A---E) Desmethylmisonidazole.
plasma concentrations of MISO and
desmethylmisonidazole remained unchanged
following dexamethasone, and, even though 4/5
patients showed higher 1 h misonidazole
concentrations following dexamethasone, the
cumulative difference did not reach statistical
significance (P>0.1). In the one patient whose
glomerular filtration rate was measured, this
remained unaltered by dexamethasone.
Discussion
Following the report that no peripheral neuropathy
was seen in the Cambridge glioma trial, when
12gm-2 MISO was given in 12 divided doses over
4 weeks (Bleehen, 1980) we reviewed the results of
MISO pharmacokinetic studies in a large group of
patients who did not have glioma. Those patients
who were not taking enzyme inducers but who were
taking steroids had a significantly lower MISO
plasma elimination half life than those not taking
steroids. Such a difference was not seen in patients
who were taking enzyme inducers, and their plasma
elimination half lives were similar to published
values for patients taking enzyme inducers..
As a result of these findings, laboratory studies
were conducted to investigate the effect of
dexamethasone on the pharmacokinetics of MISO
in laboratory animals. We have reported
(Workman, 1980a) that, in mice, the half life and
AUC of MISO, and the 0-demethylated metabolite,
desmethylmisonidazole, were unaltered by various
formulations of dexamethasone. Under certain
circumstances, however, the dexamethasone reduced
the penetration of MISO into mouse brain.
Recently, Urtasun et al. (1982) have compared two
groups of patients with glioma both groups
being given 11.25gm 2 of MISO in 9 doses over 3
weeks. One group of patients received 6 mg of
dexamethasone daily for one week prior to starting
their MISO therapy. Their results indicated a
protective effect of dexamethasone in terms of
neurotoxicity, but they failed to show any
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difference in MISO elimination half life, AUC,
percent drug recovery in urine, or peak plasma
concentrations in the patients treated with
dexamethasone. Their findings led them to
postulate that dexamethasone "protects" by
stabilising cell membranes, and altering cell surface
properties, especially in demyelinated neurones.
In our present study, the aim was to investigate
the pharmacokinetics of MISO before and after
dexamethasone. By using each patient as his/her
own control, it is easier to identify small changes in
pharmacokinetics. Previous studies (Dische et al.
1977; Workman et al., 1980b) have shown that the
pharmacokinetics of MISO do not change with
repeated administrations, and therefore any
alteration can be attributed to the effects of the
dexamethasone. The total dose of MISO used was
unlikely to produce any neurotoxicity - and such
a dose was chosen as we were not concerned with
neurotoxicity as the endpoint of this study. The
dose of dexamethasone used by us was slightly
higher than that of Urtasun et al. (1982) but was
also given for 3 weeks, and given during the
radiotherapy, not before.
The present results show a statistically significant
effect of dexamethasone on MISO kinetics. The
plasma MISO elimination half life value is almost
exactly the same as that reported in the Cambridge
glioma trial for patients who did not experience
neurotoxicity (Bleehen et al., 1981). The reduction
in elimination half life and AUC, and the rise in
urinary excretion of MISO, together with
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